Levetiracetam Teva

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
21-06-2023

Ingredient activ:

levetiracetam

Disponibil de la:

Teva B.V.

Codul ATC:

N03AX14

INN (nume internaţional):

levetiracetam

Grupul Terapeutică:

Nervous system

Zonă Terapeutică:

Epilepsy

Indicații terapeutice:

Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Teva is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Rezumat produs:

Revision: 20

Statutul autorizaţiei:

Authorised

Data de autorizare:

2011-08-25

Prospect

                                37
B. PACKAGE LEAFLET
38
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LEVETIRACETAM TEVA 250 MG FILM-COATED TABLETS
LEVETIRACETAM TEVA 500 MG FILM-COATED TABLETS
LEVETIRACETAM TEVA 750 MG FILM-COATED TABLETS
LEVETIRACETAM TEVA 1000 MG FILM-COATED TABLETS
levetiracetam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START
TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Levetiracetam Teva is and what it is used for
2.
What you need to know before you take Levetiracetam Teva
3.
How to take Levetiracetam Teva
4.
Possible side effects
5.
How to store Levetiracetam Teva
6.
Contents of the pack and other information
1.
WHAT LEVETIRACETAM TEVA IS AND WHAT IT IS USED FOR
Levetiracetam is an antiepileptic medicine (a medicine used to treat
seizures in epilepsy).
Levetiracetam Teva is used:
•
on its own in adults and adolescents from 16 years of age with newly
diagnosed epilepsy, to
treat a certain form of epilepsy. Epilepsy is a condition where the
patients have repeated fits
(seizures). Levetiracetam is used for the epilepsy form in which the
fits initially affect only
one side of the brain, but could thereafter extend to larger areas on
both sides of the brain
(partial onset seizure with or without secondary generalisation).
Levetiracetam has been given
to you by your doctor to reduce the number of fits.
•
as an add-on to other antiepileptic medicines to treat:
■
partial onset seizures with or without generalisation in adults,
adolescents, children
and infants from one month of age
■
myoclonic seizures (short, shock-like jerks of a m
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Levetiracetam Teva 250 mg film-coated tablets
Levetiracetam Teva 500 mg film-coated tablets
Levetiracetam Teva 750 mg film-coated tablets
Levetiracetam Teva 1000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Levetiracetam Teva 250 mg film-coated tablets
Each film-coated tablet contains 250 mg levetiracetam.
Levetiracetam Teva 500 mg film-coated tablets
Each film-coated tablet contains 500 mg levetiracetam.
Excipient with known effect: Each film-coated tablet contains 0.06 mg
colouring agent tartrazine
(E102).
Levetiracetam Teva 750 mg film-coated tablets
Each film-coated tablet contains 750 mg levetiracetam.
Excipient with known effect: Each film-coated tablet contains 0.35 mg
colouring agent sunset yellow
(E110).
Levetiracetam Teva 1000 mg film-coated tablets
Each film-coated tablet contains 1000 mg levetiracetam.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Levetiracetam Teva 250 mg film-coated tablets
Blue, oblong shaped, film coated tablets, scored on one side and
debossed with "9" on one side of the
score and with "3" on the other side of the score. Debossed with
"7285" on the other side of the tablet.
The scoreline is only to facilitate breaking for ease of swallowing
and not to divide into equal doses.
Levetiracetam Teva 500 mg film-coated tablets
Yellow, oblong shaped, film coated tablets, scored on one side and
debossed with "9" one side of the
score and with "3" on the other side of the score. Debossed with
"7286" on the other side of the tablet.
The scoreline is only to facilitate breaking for ease of swallowing
and not to divide into equal doses.
Levetiracetam Teva 750 mg film-coated tablets
Orange, oblong shaped, film coated tablets, scored on one side and
debossed with "9" on one side of
the score and with "3" on the other side of the score. Debossed with
"7287" on the other side of the
tablet. The scoreline is only to facilitate breaking for ease of
sw
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 21-06-2023
Raport public de evaluare Raport public de evaluare bulgară 19-08-2021
Prospect Prospect spaniolă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 21-06-2023
Raport public de evaluare Raport public de evaluare spaniolă 19-08-2021
Prospect Prospect cehă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 21-06-2023
Raport public de evaluare Raport public de evaluare cehă 19-08-2021
Prospect Prospect daneză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 21-06-2023
Raport public de evaluare Raport public de evaluare daneză 19-08-2021
Prospect Prospect germană 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului germană 21-06-2023
Raport public de evaluare Raport public de evaluare germană 19-08-2021
Prospect Prospect estoniană 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 21-06-2023
Raport public de evaluare Raport public de evaluare estoniană 19-08-2021
Prospect Prospect greacă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 21-06-2023
Raport public de evaluare Raport public de evaluare greacă 19-08-2021
Prospect Prospect franceză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 21-06-2023
Raport public de evaluare Raport public de evaluare franceză 19-08-2021
Prospect Prospect italiană 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 21-06-2023
Raport public de evaluare Raport public de evaluare italiană 19-08-2021
Prospect Prospect letonă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 21-06-2023
Raport public de evaluare Raport public de evaluare letonă 19-08-2021
Prospect Prospect lituaniană 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 21-06-2023
Raport public de evaluare Raport public de evaluare lituaniană 19-08-2021
Prospect Prospect maghiară 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 21-06-2023
Raport public de evaluare Raport public de evaluare maghiară 19-08-2021
Prospect Prospect malteză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 21-06-2023
Raport public de evaluare Raport public de evaluare malteză 19-08-2021
Prospect Prospect olandeză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 21-06-2023
Raport public de evaluare Raport public de evaluare olandeză 19-08-2021
Prospect Prospect poloneză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 21-06-2023
Raport public de evaluare Raport public de evaluare poloneză 19-08-2021
Prospect Prospect portugheză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 21-06-2023
Raport public de evaluare Raport public de evaluare portugheză 19-08-2021
Prospect Prospect română 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului română 21-06-2023
Raport public de evaluare Raport public de evaluare română 19-08-2021
Prospect Prospect slovacă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 21-06-2023
Raport public de evaluare Raport public de evaluare slovacă 19-08-2021
Prospect Prospect slovenă 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 21-06-2023
Raport public de evaluare Raport public de evaluare slovenă 19-08-2021
Prospect Prospect finlandeză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 21-06-2023
Raport public de evaluare Raport public de evaluare finlandeză 19-08-2021
Prospect Prospect suedeză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 21-06-2023
Raport public de evaluare Raport public de evaluare suedeză 04-08-2016
Prospect Prospect norvegiană 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 21-06-2023
Prospect Prospect islandeză 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 21-06-2023
Prospect Prospect croată 21-06-2023
Caracteristicilor produsului Caracteristicilor produsului croată 21-06-2023
Raport public de evaluare Raport public de evaluare croată 19-08-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor